Abstract：
UNASSIGNED: Dose reduction of biologics for psoriasis is applied in daily practice, although guidelines are lacking. Striving for clear criteria is important, as it leads to a consistent application of dose reduction.
UNASSIGNED: To achieve consensus on criteria for biologic dose reduction in psoriasis patients with stable and low disease activity.
UNASSIGNED: An online Delphi procedure (eDelphi) was conducted. Dutch dermatologists were invited to participate in a maximum of 3 voting rounds. Proposed statements were selected based on literature review and included criteria for the application of dose reduction and dosing schedules. Biologic dose reduction was defined as \'application of injection interval prolongation\'. Proposed statements were rated using a 9-point Likert scale; consensus was reached when ≥70% of all voters rated \'agree\' (7-9) and <15% rated \'disagree\' (1-3).
UNASSIGNED: A total of 27 dermatologists participated and reached a consensus on 15 recommendations over 2 voting rounds. Agreed statements included criteria for dose reduction eligibility, criteria for dose reduction (dis)continuation, and dosing schedules for adalimumab, etanercept, and ustekinumab. Based on the eDelphi outcomes, an algorithm fit for implementation in current practice was developed.
UNASSIGNED: Recommendations of this national consensus process can guide clinicians, and consequently their patients, toward consistent application of biologic dose reduction.
UNASSIGNED: To achieve consensus on criteria for biologic dose reduction in psoriasis patients with stable and low disease activity.
UNASSIGNED: An online Delphi procedure (eDelphi) was conducted. Dutch dermatologists were invited to participate in a maximum of 3 voting rounds. Proposed statements were selected based on literature review and included criteria for the application of dose reduction and dosing schedules. Biologic dose reduction was defined as \'application of injection interval prolongation\'. Proposed statements were rated using a 9-point Likert scale; consensus was reached when ≥70% of all voters rated \'agree\' (7-9) and <15% rated \'disagree\' (1-3).
UNASSIGNED: A total of 27 dermatologists participated and reached a consensus on 15 recommendations over 2 voting rounds. Agreed statements included criteria for dose reduction eligibility, criteria for dose reduction (dis)continuation, and dosing schedules for adalimumab, etanercept, and ustekinumab. Based on the eDelphi outcomes, an algorithm fit for implementation in current practice was developed.
UNASSIGNED: Recommendations of this national consensus process can guide clinicians, and consequently their patients, toward consistent application of biologic dose reduction.
摘要：
未经评估：牛皮癣生物制剂的剂量减少应用于日常实践，虽然缺乏指导方针。争取明确的标准很重要,因为它导致剂量减少的一致应用。
UNASSIGNED：在疾病活动度稳定且低的银屑病患者的生物剂量减少标准上达成共识。
UNASSIGNED：进行在线Delphi程序（eDelphi）。荷兰皮肤科医生被邀请参加最多3轮投票。根据文献综述选择拟议的陈述，并包括剂量减少和给药时间表的应用标准。生物剂量减少定义为“延长注射间隔的应用”。建议的陈述使用9分的李克特量表进行评级；当≥70％的所有选民被评为“同意”（7-9）和<15％被评为“不同意”（1-3）时，达成共识。
UNASSIGNED：共有27位皮肤科医生参加，并在2轮投票中就15项建议达成共识。商定的声明包括剂量减少资格的标准，剂量减少(DIS)持续的标准，和阿达木单抗的给药时间表，依那西普,和ustekinumab.根据eDelphi结果，开发了一种适用于当前实践的算法。
UNASSIGNED：这一国家共识过程的建议可以指导临床医生，因此他们的病人，走向一致的生物剂量减少应用。
UNASSIGNED：在疾病活动度稳定且低的银屑病患者的生物剂量减少标准上达成共识。
UNASSIGNED：进行在线Delphi程序（eDelphi）。荷兰皮肤科医生被邀请参加最多3轮投票。根据文献综述选择拟议的陈述，并包括剂量减少和给药时间表的应用标准。生物剂量减少定义为“延长注射间隔的应用”。建议的陈述使用9分的李克特量表进行评级；当≥70％的所有选民被评为“同意”（7-9）和<15％被评为“不同意”（1-3）时，达成共识。
UNASSIGNED：共有27位皮肤科医生参加，并在2轮投票中就15项建议达成共识。商定的声明包括剂量减少资格的标准，剂量减少(DIS)持续的标准，和阿达木单抗的给药时间表，依那西普,和ustekinumab.根据eDelphi结果，开发了一种适用于当前实践的算法。
UNASSIGNED：这一国家共识过程的建议可以指导临床医生，因此他们的病人，走向一致的生物剂量减少应用。
